These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Sildenafil in patients with cardiovascular disease. Brindis RG; Kloner RA Am J Cardiol; 2003 Nov; 92(9A):26M-36M. PubMed ID: 14609621 [TBL] [Abstract][Full Text] [Related]
5. Sildenafil is a pulmonary vasodilator in awake lambs with acute pulmonary hypertension. Weimann J; Ullrich R; Hromi J; Fujino Y; Clark MW; Bloch KD; Zapol WM Anesthesiology; 2000 Jun; 92(6):1702-12. PubMed ID: 10839922 [TBL] [Abstract][Full Text] [Related]
6. Effects of sildenafil citrate on human hemodynamics. Jackson G; Benjamin N; Jackson N; Allen MJ Am J Cardiol; 1999 Mar; 83(5A):13C-20C. PubMed ID: 10078538 [TBL] [Abstract][Full Text] [Related]
7. Cyclic GMP phosphodiesterase-5: target of sildenafil. Corbin JD; Francis SH J Biol Chem; 1999 May; 274(20):13729-32. PubMed ID: 10318772 [No Abstract] [Full Text] [Related]
8. Effect of sildenafil on coronary active and reactive hyperemia. Chen Y; Du R; Traverse JH; Bache RJ Am J Physiol Heart Circ Physiol; 2000 Nov; 279(5):H2319-25. PubMed ID: 11045968 [TBL] [Abstract][Full Text] [Related]
9. Electropharmacologic effects of a new phosphodiesterase III inhibitor, toborinone (OPC-18790), assessed in an in vivo canine model. Sugiyama A; Satoh Y; Hashimoto K J Cardiovasc Pharmacol; 2001 Aug; 38(2):268-77. PubMed ID: 11483877 [TBL] [Abstract][Full Text] [Related]
10. In vivo canine model comparison of cardiohemodynamic and electrophysiological effects of a new antipsychotic drug aripiprazole (OPC-14597) to haloperidol. Sugiyama A; Satoh Y; Hashimoto K Toxicol Appl Pharmacol; 2001 Jun; 173(2):120-8. PubMed ID: 11384214 [TBL] [Abstract][Full Text] [Related]
11. The pharmacology of sildenafil, a novel and selective inhibitor of phosphodiesterase (PDE) type 5. Wallis RM Nihon Yakurigaku Zasshi; 1999 Oct; 114 Suppl 1():22P-26P. PubMed ID: 10629850 [TBL] [Abstract][Full Text] [Related]
12. Cyclic nucleotide phosphodiesterase type 5 activity limits blood flow to hypoperfused myocardium during exercise. Traverse JH; Chen YJ; Du R; Bache RJ Circulation; 2000 Dec; 102(24):2997-3002. PubMed ID: 11113052 [TBL] [Abstract][Full Text] [Related]
13. Sympathetic activation by sildenafil. Phillips BG; Kato M; Pesek CA; Winnicki M; Narkiewicz K; Davison D; Somers VK Circulation; 2000 Dec; 102(25):3068-73. PubMed ID: 11120696 [TBL] [Abstract][Full Text] [Related]
14. Effects of combined treatment with sildenafil and itraconazole on the cardiovascular system in telemetered conscious dogs. Kim EJ; Seo JW; Hwang JY; Han SS Drug Chem Toxicol; 2005; 28(2):177-86. PubMed ID: 15865259 [TBL] [Abstract][Full Text] [Related]
15. Overall cardiovascular profile of sildenafil citrate. Zusman RM; Morales A; Glasser DB; Osterloh IH Am J Cardiol; 1999 Mar; 83(5A):35C-44C. PubMed ID: 10078541 [TBL] [Abstract][Full Text] [Related]
17. Effects of sildenafil on cardiac repolarization. Chiang CE; Luk HN; Wang TM; Ding PY Cardiovasc Res; 2002 Aug; 55(2):290-9. PubMed ID: 12123768 [TBL] [Abstract][Full Text] [Related]
18. Effect of PDE5 inhibition combined with free oxygen radical scavenger therapy on erectile function in a diabetic animal model. De Young L; Yu D; Freeman D; Brock GB Int J Impot Res; 2003 Oct; 15(5):347-54. PubMed ID: 14562136 [TBL] [Abstract][Full Text] [Related]
19. N-3-substituted imidazoquinazolinones: potent and selective PDE5 inhibitors as potential agents for treatment of erectile dysfunction. Rotella DP; Sun Z; Zhu Y; Krupinski J; Pongrac R; Seliger L; Normandin D; Macor JE J Med Chem; 2000 Apr; 43(7):1257-63. PubMed ID: 10753463 [TBL] [Abstract][Full Text] [Related]
20. Peripheral and central activation of nitric oxide-cyclic GMP pathway by sildenafil. Patil CS; Singh VP; Kulkarni SK Inflammopharmacology; 2005; 13(5-6):467-78. PubMed ID: 16280099 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]